Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 45.79M P/E - EPS this Y -12.70% Ern Qtrly Grth -
Income -20.7M Forward P/E -1.60 EPS next Y -2.00% 50D Avg Chg -20.00%
Sales 7.6M PEG - EPS past 5Y - 200D Avg Chg -61.00%
Dividend N/A Price/Book 11.38 EPS next 5Y - 52W High Chg -79.00%
Recommedations 1.70 Quick Ratio 4.29 Shares Outstanding 20.54M 52W Low Chg 6.00%
Insider Own 0.09% ROA -33.87% Shares Float 15.71M Beta 1.50
Inst Own 11.64% ROE -85.70% Shares Shorted/Prior 0.92M/1M Price 2.23
Gross Margin 97.37% Profit Margin -272.36% Avg. Volume 309,030 Target Price 13.75
Oper. Margin -257.82% Earnings Date May 11 Volume 85,900 Change -1.33%
SELLAS Life Sciences Group, Inc News
06/27/22 SELLAS Life Sciences Provides Clinical Update for GFH009 Ongoing Phase 1 Clinical Trial
06/08/22 SELLAS Life Sciences's Galinpepimut/Opdivo Combo Shows Increased Survival In Mesothelioma Patients
06/08/22 SELLAS Life Sciences Reports Encouraging Updated Clinical Data Indicating Increased Survival from Ongoing Phase 1 Mesothelioma Study of Galinpepimut-S Combined with Opdivo
06/02/22 SELLAS Life Sciences to Present at the JMP Securities Life Sciences Conference on June 15th
05/26/22 Sellas' Ovarian Cancer Candidate Shows Clinical Benefit In Pretreated Patients
05/26/22 SELLAS Reports Preliminary Data Showing Clinical Benefit from Phase 1/2 Clinical Trial of Galinpepimut-S (GPS) in Combination with Keytruda® in Patients with WT1+ Advanced Ovarian Cancer
05/12/22 SELLAS Life Sciences Reports First Quarter 2022 Financial Results and Provides Business Update
04/26/22 SELLAS Life Sciences Launches Expanded Access Program for Galinpepimut-S
04/11/22 SELLAS Life Sciences’ Newly Licensed GFH009 Asset Shows Significant Anti-Leukemic Effect in Acute Myeloid Leukemia Patients Relapsed/Refractory to Venetoclax in Ongoing Phase 1 Study
04/06/22 SELLAS Life Sciences Announces Achievement of Development Milestone for Approval of IND for Galinpepimut-S in China
04/05/22 SELLAS Life Sciences Provides Business Update and First Quarter 2022 Highlights
04/01/22 SELLAS Life Sciences Stock Plunges After $25M Capital Raise Via Equity, In-Licenses Cancer-Focused CDK9 Inhibitor
03/31/22 SELLAS Life Sciences Announces Pricing of $25.0 Million Underwritten Public Offering
03/31/22 SELLAS Life Sciences Announces Proposed Underwritten Public Offering
03/31/22 SELLAS Life Sciences Signs Exclusive License Agreement with GenFleet Therapeutics for Next-Generation, Highly Selective CDK9 Inhibitor
03/21/22 SELLAS Life Sciences Group (NASDAQ:SLS) adds US$28m to market cap in the past 7 days, though investors from three years ago are still down 88%
03/14/22 SELLAS Life Sciences Expands Executive Team with Appointment of Robert Francomano as Chief Commercial Officer
02/28/22 SELLAS Life Sciences Announces Final Court Approval of Settlement of Securities Litigation
02/01/22 SELLAS Life Sciences Announces Completion of Enrollment of Phase 1/2 Clinical Trial of GPS in Combination with Pembrolizumab in Advanced Metastatic Ovarian Cancer

SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. The company was founded in 2012 and is headquartered in New York, New York.

SLS Chatroom

User Image Imbackbears Posted - 1 hour ago

$SLS cantor lowers price target to 6.00 bucks. Looks like the shanghai born Chinese Anyalsts agent for the CCP is on track for the Chinese investors to buyout sellas for 6.50 to 8 bucks a share.

User Image BigPharma Posted - 3 hours ago

$SLS Interesting this Seeking Alpha articl featuring both BMS and Merck has a big write up with Sellas. Opdivo is continuing to grow sales too, and it is reasonably probable that multiple combination therapies will be tested and approved in the coming years. For example, SELLAS Life Sciences (NASDAQ:SLS) recently reported updated data from a phase 1 trial of its galinpepimut-S drug in combination with BMY's Opdivo. https://seekingalpha.com/article/4520830-bristol-myers-is-melting-up-again

User Image Imbackbears Posted - 5 hours ago

$SLS I bet we get early FDA approval late next year on gfh009 https://www.targetedonc.com/view/gfh009-demonstrate-early-efficacy-in-relapsed-refractory-lymphoma-and-aml

User Image Tzfloygined Posted - 5 hours ago

$SLS @GeorgeTheo I still am a share holder

User Image GeorgeTheo Posted - 5 hours ago

$SLS $BMY Interesting SA article Suggesting BMY will be generating Future revenue utilizing Gps in Combination with Opdivo... Meanwhile $MRK would love to have rights to Gps for Ovarian Cancer Patients. Opdivo is continuing to grow sales too, and it is reasonably probable that multiple combination therapies will be tested and approved in the coming years. For example, SELLAS Life Sciences recently reported updated data from a phase 1 trial of its galinpepimut-S drug in combination with BMY's Opdivo. The data suggested and increased survival rate in patients with malignant pleural mesothelioma ("MPM") who either relapsed or were resistant to treatment after at least one line of standard of care chemotherapy. "This updated data is very encouraging, as it not only confirms our data reported in June 2021, but now reflects an increased survival benefit even though almost all additionally enrolled patients had Grade III and IV malignant mesothelioma," https://seekingalpha.com/article/4520830-bristol-myers-is-melting-up-again

User Image Tzfloygined Posted - 6 hours ago

$SLS slow bleed

User Image betbetsgold Posted - 6 hours ago

$SLS https://www.linkedin.com/posts/sellas-life-sciences_gfh009-demonstrate-early-efficacy-in-relapsed-activity-6948332272131457024-Ub2y?utm_source=linkedin_share&utm_medium=ios_app

User Image GeorgeTheo Posted - 6 hours ago

$SLS Shaping up to be an amazing end of 2022 - Preliminary List of "Known" Catalysts 1. Final Phase 2 Gps Keytruda Combination Results by the End of the Year. Partnership + upfront money potential MRK Joint Analysis Immunological data supporting the specific action of GPS in extending disease free survival and overall survival presented in an 'upcoming medical conference' (July - August) https://www.reddit.com/r/sellaslifesciences/comments/uy75zj/from_angelo_on_ovariancancer_combo_data_keytruda/ 2. Final Memorial Sloan Kettering Gps Opdivo Mesothelioma Results by the end of the year BMY Partnership + upfront Money potential - more than doubling life expectancy 3. REGAL Enrollment Complete by the end of the year - This will bring all the big money to the party. It will start the clock ticking on billions in additional Market capitalization for SLS 4. GFH009 Trial Safety Data complete by the end of the year - CDK9 Efficacy has been established many times over, safety has been the issue. 5. 5, 3D MED Trials Launching, by the end of the Year, $5M Milestones

User Image GeorgeTheo Posted - 6 hours ago

$SLS cont. 6. Possible IDMC Halt for Efficacy - any time More likely than not 32 months deep into a trial where the Lead investigator is Requesting expanded Access, and Control arm patients are on known therapies, with known survival rates of only 5.4 months, and the CEO has repeatedly stated the IDMC can halt the trial at any time if they see a clear Efficacy signal. Gps Moffitt Center Phase 2 OS of 21 months. The incessant short blather, by fake long, short tools, it's All intended to Frighten investment - FOR A REASON. Shorts Need our Shares and we are at the bottom. The GPS FDA Green light is Virtually Certain along with a $2 or 3B market cap in the next few quarters (this includes covid delays) - and with the cash on hand plus additional $50M in Milestone money there will be no Cheap Offerings to Save the Lowlife Lock SOME IN Now.

User Image cb5000calls Posted - 7 hours ago

$SLS Money Flow Index on the weekly now sitting at 7.07... the most extreme oversold level it's been at since 11.62 back in September of 2018... "The overbought and oversold levels are also used to signal possible trading opportunities. Moves below 10 and above 90 are rare. Traders watch for the MFI to move back above 10 to signal a long trade, and to drop below 90 to signal a short trade." "Moves above 90 and below 10 are rare occurrences that suggest a price move is unsustainable." JB Hunt ($JBHT) became oversold when the Money Flow Index moved below 10 in late October 2009 and early February 2010. The preceding declines were sharp enough to produce these readings, but the oversold extremes suggested that these declines were unsustainable. $XBI $SPY @Lionmaster @ACInvestorBlog @ProfessorDman1

User Image Imbackbears Posted - 7 hours ago

$SLS badder is like a typical short. Pollutes the board with nonsense and provides no DD . Seriously get a life

User Image Imbackbears Posted - 7 hours ago

$SLS hilarious Badder comes on here to insult forum members, I guess he h as a reputation to hold up in discord where people have no life .

User Image The_MBA Posted - 7 hours ago

$SLS Heard this week a couple things. Later this year the CDC anticipates the flu will hospitalize more than Covid. And also a major hospital saw a sharp decline in earnings due to lack of Covid patients. So Sterg, you can go ahead in future ERs and PRs remove the disclaimer about Covid impacting operations like has been done for the last two years with Regal. It's over and no longer an excuse for any company, so go ahead and remove the language.

User Image cb5000calls Posted - 7 hours ago

$SLS low volume all day long and NAS held back 7,284 shares bought so they could all clear at the end of the day.... hmmm amazing how that works.

User Image JustHereForTheMoney Posted - 7 hours ago

$SLS I hate you guys so damn much

User Image cb5000calls Posted - 8 hours ago

$SLS huge buy side inbalance....

User Image Imbackbears Posted - 8 hours ago

$SLS Biden Sucks https://www.cnbc.com/2022/06/29/stock-market-futures-open-to-close-news.html

User Image cb5000calls Posted - 9 hours ago

$SLS Wilms Tumor Protein Market Forecast, Global Industry Analysis and Opportunity Assessment 2022-2028 $GSK $INO $OTSKY https://hightimbertimes.com/uncategorized/wilms-tumor-protein-market-forecast-global-industry-analysis-and-opportunity-assessment-2022-2028-glaxosmithkline-plc-inovio-pharmaceuticals-inc-otsuka-holdings-co-ltd/304784/

User Image AS1980 Posted - 9 hours ago

$SLS dead shit

User Image cb5000calls Posted - 9 hours ago

$SLS don't forget these were bought back on April 1st.... huge $7.50 sweep calls. Price currently suppressed down to $2.26 https://fintel.io/sof/us/sls $XBI $LABU $IBB

User Image Imbackbears Posted - 9 hours ago

$SLS $MRK or $BMY Forgot to mention this today. Merck stop being a cheap ass and buy ASAP Sellas Life Sciences that has outstanding Cancer Immunotherapy trial results that is saving lives so you can get this finished and out to the people who are dying !

User Image cb5000calls Posted - 9 hours ago

$SLS retail ownership continues to dwindle lower and lower... https://fintel.io/sro/us/sls

User Image Imbackbears Posted - 9 hours ago

$SLS You all are morons if you think this will go below the 52 week low of 2.10 ever again. Sterg needs to get more institutional buyers , but this wont happen until phase 3 data is released , all the institutions invested are 5.50-9 dollar range owning over 100k shares. Completely useless to short as this will trade sideways , XBI would need to be well above 80 to see any movement up Until inflation is fixed by joe biden by lowering gas prices back to 3 bucks and below this economy will always suck period. Right now our world leader is worried about gun laws and abortion law roe vs wade. He could care less about the people losing over half their retirements in 401k and the stock market. Next time vote republican you Schmucks

User Image PMD777 Posted - 9 hours ago

$SLS come on cb there’s 5 lots on the bid at 2.25 that I know is your short.

User Image PMD777 Posted - 10 hours ago

$SLS man - so xbi fully recovers and we're back to the broken record...red. Should be 2.40 today if cb would stop manipulating....

User Image cb5000calls Posted - 10 hours ago

$SLS 🤫hahahahahah he's so unhinged it's priceless. When was the last time he actually posted any DD, a news article, a PR, commented about the company, the hires, etc? Literally anything related to the company versus trying to attack real longs.... crickets....

User Image Imbackbears Posted - 10 hours ago

$SLS I don't see this going below a 52 week low unless something like bad news is released by sellas 95% chance they won't in 2022 or 2023. Or the market has another crash that was not predicted like another .50 or .75 basis point hike sometime in 4th qtr after this summer. But I think we will be above 3 before this happens. No way we are going below 2.10 anytime soon if ever

User Image cb5000calls Posted - 11 hours ago

$SLS 🤫shhhhhhhhh

User Image cb5000calls Posted - 11 hours ago

$SLS got to love how we have fake "longs" parading around claiming their proof is trade history as they sold 250 shares at $2.15. That's not proof of being long, they aren't real longs they are POS shorts. Then you have real longs actually buying... the same fake "longs" that complain about real longs posting on one ticker surprisingly only post on one ticker and are also surprisingly the most vocal when the price moves up.... hmmm I wonder who's trying to spin a fake narrative. Remember when that fake "long" was posting screenshots of buying 5 shares and claimed that was his proof hahahahahahah

User Image GeorgeTheo Posted - 11 hours ago

$SLS FDA Green light to $800M in AML revenue by the First Half 2,500% to 5,000% ROI Potential - Jazz paid $1.5B for Cpxx, SLS's current over shorted MC $.047b Cash Runway out almost 2 years: + $55M in Scheduled Milestones in the next 12 months along with a tiny $6M qtrly burn rate. Does anyone know if the Regulatory Job Listing today is because the IDMC is going to halt the trial for Efficacy?

Analyst Ratings
Cantor Fitzgerald Overweight Jul 21, 21
Maxim Group Buy Nov 18, 19
Alliance Global Partners Buy Nov 18, 19
Oppenheimer Outperform Nov 18, 19
Maxim Group Buy Nov 18, 19
H.C. Wainwright Buy Nov 18, 19
Maxim Group Buy Nov 18, 19